Search

Displaying results 3981 - 3990 of 6076 in total
  1. Drug

    Beinaglutide

    go.drugbank.com/drugs/DB15072
    Investigational

    Beinaglutide is under investigation in clinical trial NCT03829891 (Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus).

  2. Drug

    Citarinostat

    go.drugbank.com/drugs/DB15449
    Investigational

    Citarinostat is under investigation in clinical trial NCT02886065 (A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM).

  3. Drug

    PF-04457845

    go.drugbank.com/drugs/DB12012
    Investigational

    PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence.

  4. Drug

    Gemigliptin

    go.drugbank.com/drugs/DB12412
    Investigational

    Gemigliptin has been investigated for the treatment of Cancer and Cisplatin Adverse Reaction.

  5. Drug

    Serotonin

    go.drugbank.com/drugs/DB08839
    InvestigationalNutraceutical

    For temporary relief of nervousness, anxiety, mood swings, joint pains, weakness, drowsiness, itching and lethargy. Not evaluated by the FDA, homeopathic product.

  6. Drug

    Pexiganan

    go.drugbank.com/drugs/DB16293
    Investigational

    Pexiganan is under investigation in clinical trial NCT01594762 (Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers).

  7. Drug

    Epratuzumab

    go.drugbank.com/drugs/DB04958
    Investigational

    This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.

  8. Drug

    VLTS-934

    go.drugbank.com/drugs/DB05597
    Investigational

    VLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).

  9. Drug

    PR006

    go.drugbank.com/drugs/DB17002
    Experimental

    It is being investigated for the treatment of dementia.

  10. Drug

    LY3884961

    go.drugbank.com/drugs/DB17070
    Investigational

    LY3884961 (previously PR001) is being developed by Prevail Therapeutics as a single-dose gene therapy for patients with Parkinson's disease and Gaucher disease.[L43468]